Caliper Sells Two Product Lines to Biotage | GenomeWeb

a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — Continuing its strategy to divest non-core parts of its business, Caliper Life Sciences today announced it has reached an agreement to sell its RapidTrace solid phase extraction and TurboVap evaporation product lines to Biotage for $16.5 million in cash.

Biotage also assumes liabilities of about $500,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.